GU Cancers 2023 | IMvigor130: 1L atezolizumab +/- chemotherapy in metastatic urothelial carcinoma

Aristotelis Bamias, MD, National and Kapodistrian University of Athens, Athens, Greece, shares the final overall-survival (OS) results of the Phase III IMvigor130 (NCT03547973) trial evaluating atezolizumab with or without chemotherapy in metastatic urothelial carcinoma. Previously, atezolizumab has been demonstrated to induce sustained response in metastatic urothelial carcinoma. Coprimary endpoints were progression-free survival (PFS) and overall-survival (OS). Secondary endpoints include duration of response (DOR)and percentage of participants with best overall response of complete response (CR). This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.